Trillium Therapeutics Advances TTI-621 Into Phase 1b Cohort Expansion Enrollment
TORONTO, ONTARIO--(Marketwired - Nov 2, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, has advanced its novel investigational drug TTI-621, a …